• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    G

    Gerash University of Medical Sciences

    院校EST. 1989
    5,551论文总数
    6.6万引用总数

    论文量&引用量时间轴

    机构学者

    论文(5551)

    年份
    起
    –
    止
    排序
    1Nanotechnology for the Treatment of Iron Deficiency Anemia: an in Vivo Review.
    Erfan Haghighatseir,Zeinab Karimi,Aydin Berenjian,Alireza Ebrahiminezhad

    Iron deficiency is the most prevalent nutritional disorder globally. Conventional treatment primarily involves oral supplementation with various iron salts, such as ferrous sulfate. While cost-effective and easily administered, these salts are associated with several challenges, including gastrointestinal irritation, prolonged treatment duration, and poor patient compliance due to adverse side effects. To address these limitations, nanotechnology has been employed to develop improved oral iron supplements with varying degrees of success. Utilizing approaches from nanotechnology and materials science, researchers have engineered diverse iron-containing nanomaterials designed to provide bioavailable iron. However, the efficacy of these nanomaterials as oral supplements is highly dependent on their specific physicochemical properties. An effective nano-based replacement for iron salts must exhibit high bioavailability for efficient iron restoration and low toxicity to minimize side effects. This review consolidates in vivo research on various iron nanomaterials evaluated as oral iron supplements. Furthermore, it proposes a framework for the ideal characteristics of an oral iron nanoparticle supplement by consolidating the current understanding of the mechanisms governing nanoparticle absorption and toxicity.

    2026BioMetals(2026)引用:86
    引用
    AI阅读
    加入学术空间
    2Probabilistic Risk Assessment of Occupational Exposure to Respirable Crystalline Silica among Ceramic Workers in an Industrial Town in Iran: a Monte Carlo Simulation Approach
    Saeed Saeedizadeh,Mohammad Javad Assari,Farshid Ghorbani-Shahna,Javad Faradmal, Zohreh Karami,Majid Habibi Mohraz

    This study aimed to evaluate occupational exposure to respirable crystalline silica (RCS) and assess the lifetime cancer risk (ILCR) and non-cancer hazard quotient (HQ) among ceramic workers. A cross-sectional study was conducted across four occupational groups: polisher/washer, finisher, caster, and material handler. Personal air sampling was performed using NIOSH 7602 methodology to measure time-weighted average (TWA) RCS concentrations. ILCR and HQ were calculated using Monte Carlo simulation with 10,000 iterations, incorporating exposure parameters and health risk models from USEPA guidelines. The mean concentration of respirable crystalline silica (RCS) among workers exceeded both Iran OEL and threshold limit value (TLV) in all four occupational groups, with the highest level observed in Polishers (2.76 mg/m3). Monte Carlo simulation revealed that all groups had Incremental Lifetime Cancer Risk (ILCR) values above the acceptable threshold of 1.00E-06, with polishers showing the highest mean ILCR (5.66E-04). Similarly, Hazard Quotients (HQ) exceeded in all groups, indicating significant non-cancer health risks, particularly in Polishers (mean HQ = 114). These findings indicate a high probability of developing silica-related diseases such as silicosis and lung cancer, emphasizing the need for immediate control measures. The results demonstrate that ceramic workers are exposed to hazardous levels of respirable crystalline silica, posing serious long-term health risks. The use of Monte Carlo simulation provided robust estimates of both carcinogenic and non-carcinogenic risk, confirming the urgent need for regulatory enforcement, engineering controls, respiratory protection, and targeted health education to prevent silica-related diseases in this high-risk population.

    2026引用:2
    引用
    AI阅读
    加入学术空间
    3Impact of Alcohol Consumption, Substance Use, and Smoking on Treatment Outcomes in Tuberculosis: a Systematic Review and Meta-Analysis.
    Bahram Heshmati, Sanaz Omidi,Younes Mohammadi

    This study aimed to elucidate the influence of alcohol, smoking, and substance use on tuberculosis (TB) treatment failure using a meta-analysis approach. A comprehensive search strategy was developed and applied to three major databases: MEDLINE, Web of Science, and Scopus. Additionally, Google Scholar, and Google were used to locate grey literature. Studies were identified through title and abstract screening, followed by a full-text review for eligibility. The Newcastle–Ottawa Scale checklist was employed to assess the quality of included studies. Pooled odds ratios (OR) with 95

    2026Systematic Reviews(2026)引用:2
    引用
    AI阅读
    加入学术空间
    4Emerging Strategies to Reduce the Side Effects of CAR-T Cell Therapy: Focusing on Gene Editing and Nanotechnology
    Jinxin Dong, Denis Andreevich Nikolenko, Shuxrat Boymuradov, Lilya Garifulina, Elnaz Khodabandehloo

    CAR-T cell therapy has been transformative in treating certain blood malignancies and is also being adopted for treating other malignancies, including solid tumors. Despite its undeniable successes, CAR-T cell therapy is frequently associated with severe and potentially life-threatening side effects and toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), graft-versus-host disease (GvHD) in allogeneic settings, secondary CAR-T-derived malignancies, and long-term immunosuppression-induced risk of infections. Recent advances in integrating gene-editing technology and nanomedicine into CAR-T cell therapy have opened new avenues to enhance the safety profile of CAR-T cell therapy and broaden its clinical applications. Gene-editing tools enable targeted modulation of the CAR-T cells' genome, thereby improving their safety profile by preventing related side effects. In parallel, nanomedicine can be used at various stages, including manufacturing and post-treatment, to prevent their occurrence or manage them. This review highlights the current preclinical and clinical landscape, explores the emerging combinatorial strategies, and discusses future directions to achieve a safe and more controllable CAR-T cell therapy.

    2026Clinical and Translational Oncology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    5Unlocking the Healing Power of Berberine: A Promising Aid for Multiple Sclerosis.
    Amir Modarresi Chahardehi, Negar Karimi Khordeh, Narges Moazeni Limoudehi, Hediyeh Dasoomi, Razie Omrani, Mohammadhadi Nikjoo, Elham Mortazavi Mamaghani, Reza Nasiri, Mohammad Saeed Soleimani Meigoli, Fatemeh Shoja, Zahra Jafari-Ardakan,Reza Arefnezhad,

    Multiple sclerosis (MS) is a debilitating autoimmune disorder characterized by inflammatory demyelination and progressive neurodegeneration within the central nervous system (CNS). Despite advances in disease-modifying therapies (DMTs), current treatments primarily mitigate relapses and slow disease progression but fall short in comprehensively addressing cumulative disability or neurodegeneration. Berberine (BBR), a naturally occurring isoquinoline alkaloid, has emerged as a promising therapeutic candidate due to its potent immunomodulatory, anti-inflammatory, and neuroprotective properties. In this narrative review, we synthesize the molecular mechanisms underpinning BBR's effects on MS pathology and evaluate preclinical evidence from MS-relevant animal models. Studies in experimental autoimmune encephalomyelitis (EAE) -the primary MS model-and the cuprizone (CPZ) -induced demyelination model demonstrate that BBR (typically 5-300 mg/kg in preclinical protocols) reduces pro-inflammatory cytokines, modulates immune responses, and promotes remyelination-processes critical for counteracting MS-associated neurodegeneration. BBR modulates key signaling pathways, including JAK/STAT and SPHK1/S1P, which are pivotal in attenuating immune-mediated damage and preserving blood-brain barrier (BBB) integrity. Despite its therapeutic potential, challenges such as poor bioavailability and suboptimal pharmacokinetics have spurred investigations into advanced delivery systems. Nanoformulations, particularly BBR-loaded iron oxide nanoparticles (BBR-IONP), have shown superior efficacy in preclinical models by enhancing CNS delivery and improving remyelination outcomes. By highlighting BBR's multifaceted bioactivities, this review underscores its promise as a complementary or alternative approach to address unmet needs in MS management, while acknowledging the critical need for clinical trials to validate these preclinical findings.

    2026IBRO neuroscience reports(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 5551 篇论文

    合作机构(100)

    德黑兰医科大学合作论文 540
    沙希德贝赫什蒂医科大学合作论文 471
    伊斯兰自由大学合作论文 344
    克尔曼沙赫医学科学大学合作论文 268
    伊朗医科大学合作论文 257
    设拉子医科大学合作论文 239
    大不里士医科大学合作论文 210
    伊斯法罕医科大学合作论文 147
    阿瓦士医疗科学大学合作论文 146
    Hamedan University of Medical Sciences合作论文 116

    机构统计